Bashar Al Jayyousi, MD
Interventional Cardiology · Saginaw, MINPI 1225292568
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,211 of the $7,066 with a category attached, or 73.7%. It is spread thinly across 38 manufacturers, the largest accounting for just 22.0%. Reporting peaked in 2019 at $2,698 and has fallen 80.6% since, to $524 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MI, where the typical reported total is $6,857.
Across 228 payments — averaging $30.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Boston Scientific$1K
- Novartis$398
- Shockwave Medical, Inc$377
- Pfizer$324
- Abbott$305
- plus $3K from 32 others
Across 49 payments — averaging $1079.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- W. L. Gore & Associates, Inc.$28K
- CSL Behring$20K
- Cardiovascular Systems Inc.$4K
What the payments were for
- Travel & lodging$1,75525%
- Food & beverage$5,21174%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 22 | $1,553 |
| Boston Scientific | 19 | $1,487 |
| Novartis | 24 | $398 |
| Shockwave Medical, Inc | 8 | $377 |
| Pfizer | 20 | $324 |
| Abbott | 18 | $305 |
| Astellas Pharma US Inc | 10 | $295 |
| Medtronic(3 entities) | 8 | $293 |
| Johnson & Johnson | 13 | $259 |
| E.r. Squibb & Sons, L.L.C. | 14 | $229 |
| Novo Nordisk | 2 | $211 |
| Boehringer Ingelheim | 7 | $122 |
| Amgen | 7 | $118 |
| Abiomed | 1 | $116 |
| Philips North America LLC | 3 | $100 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $88 |
| Siemens Medical Solutions USA, Inc. | 5 | $85 |
| Cardiovascular Systems Inc. | 5 | $80 |
| Actelion Pharmaceuticals US, Inc. | 3 | $64 |
| Cardiva Medical, Inc. | 3 | $59 |
| Lundbeck LLC | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| AstraZeneca | 3 | $37 |
| Bracco Diagnostics Inc. | 2 | $36 |
| Biosense Webster, Inc. | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Bayer | 1 | $30 |
| Teleflex LLC | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Heartflow, Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Biotronik Inc. | 1 | $18 |
| ZOLL Circulation Inc | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $14 |
| Baylis Medical Company Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,066 in reported general payments places this provider in the 50th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 366 | $443,112 |
| Repatha SureclickEvolocumab | 86 | $106,545 |
| XareltoRivaroxaban | 103 | $103,842 |
| EntrestoSacubitril/Valsartan | 61 | $71,692 |
| BrilintaTicagrelor | 54 | $41,639 |
| JardianceEmpagliflozin | 36 | $37,650 |
| Praluent PenAlirocumab | 27 | $23,364 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $9,599 |
| Atorvastatin Calcium | 371 | $8,181 |
| Rosuvastatin Calcium | 207 | $5,360 |
| Ezetimibe | 118 | $4,696 |
| Metoprolol Succinate | 184 | $4,301 |
| Losartan Potassium | 226 | $4,157 |
| ClopidogrelClopidogrel Bisulfate | 196 | $3,277 |
| Ranolazine ErRanolazine | 22 | $2,940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $324 | $443,112366 claims |
| Johnson & JohnsonXarelto | $259 | $103,842103 claims |
| NovartisEntresto | $398 | $71,69261 claims |
| AstraZenecaBrilinta | $37 | $41,63954 claims |
| Boehringer IngelheimJardiance | $122 | $37,65036 claims |
| Esperion Therapeutics, Inc.Nexlizet | $33 | $9,59911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Saginaw
- Safwan KassasSaginaw$340K
- Daniel LeeSaginaw$190K
- Amer KadriSaginaw$42K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.